Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02098473 | Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis | PHASE2 | COMPLETED | 100 | — | — | Aug 31, 2014 | Jan 30, 2017 | May 9, 2017 | 30 | United States, Canada +1 |
| Arm | Type | Description |
|---|---|---|
| RPC4046 Low Dose | EXPERIMENTAL | intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose |
| RPC4046 High Dose | EXPERIMENTAL | intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose |
| Placebo | PLACEBO_COMPARATOR | intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks |
| Name | Type | Description |
|---|---|---|
| RPC4046 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Histologic evidence of EoE * Clinical symptoms of EoE including dysphagia Exclusion Criteria: * Primary causes of esophageal eosinophilia other than EoE
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tezepelumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | dupilumab, Dupilumab |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | PHASE2 | Vonoprazan |
| Eupraxia Pharmaceuticals, Inc. | EPRX | 1 | PHASE1 | EP-104GI |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Dupilumab |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | — | Undisclosed |